Summary
Definition
History and exam
Key diagnostic factors
- family history of NF1
- pain, any location
- neurological deficits: gross motor delay, general incoordination, school performance problems
- compromised vision
- compromised social interactions
- skin: café au lait spots, axillary freckling, cutaneous juvenile xanthogranulomas, neurofibromas
- head and neck: unilateral diffuse plexiform neurofibroma divisions of the trigeminal nerve
- ophthalmological: visual compromise, optic disc pallor, iris Lisch nodules
- central nervous system: signs of hydrocephalus, brain tumours, and/or cerebellar abnormalities
- peripheral nervous system: palpable mass about neck, brachial plexuses, groin, Hunter's canal, or the popliteal fossae
- skeletal: tibial dysplasia or pseudarthrosis, sphenoid wing dysplasia, pectus excavatum or carinatum, genu valgum or varum, ankle valgus, pes planus
- gastrointestinal: severe constipation, obstipation, abdominal pain, gastrointestinal bleeding
- vascular: neurological problems, abdominal pain (and/or haemorrhage)
- autism spectrum disorder
- vascular: hypertension
Risk factors
- parent with NF1
- severe crush trauma
Diagnostic investigations
1st investigations to order
- MRI and/or CT scans
- PET scan
- biopsy
- genetic testing to confirm NF1 mutation
Treatment algorithm
phaeochromocytoma
malignant peripheral nerve sheath tumour
neurofibromas: non-cutaneous
cutaneous
headache
nervous system
eye
oral
skeletal
vascular
gastrointestinal
haematopoietic
psychological
pregnancy-related
Contributors
Authors
D. Gareth Evans, MD, FRCP
Professor of Medical Genetics and Cancer Epidemiology
Genomic Medicine
School of Medicine
University of Manchester
Manchester
UK
Disclosures
DGE is an author of several studies referenced in this topic. He receives consultancies from Astrazeneca, Springworks, and Recursion. These may impact on recommendations for MEKi treatment.
Acknowledgements
Professor D. Gareth Evans would like to gratefully acknowledge Dr Vincent M. Riccardi, a previous contributor to this topic.
Disclosures
VMR is an author of several studies referenced in this topic.
Peer reviewers
Bruce R. Korf, MD, PhD
Professor
Department of Genetics
University of Alabama at Birmingham
Birmingham
AL
Disclosures
BRK declares that he has no competing interests.
Patrick Morrison, MD
Consultant in Clinical Genetics
Department of Medical Genetics
Belfast HSC Trust
Belfast
UK
Disclosures
PM declares that he has no competing interests.
Edward S. Tobias, BSc (Hons), MBChB, MRCP (UK), PhD
Clinical Senior Lecturer and Honorary Consultant in Medical Genetics
Institute of Medical Genetics
Yorkhill Hospital
University of Glasgow
Scotland
UK
Disclosures
EST declares that he has no competing interests.
Differentials
- Neurofibromatosis type 2 (NF2)
- McCune-Albright syndrome
- Familial café au lait spots
More DifferentialsGuidelines
- Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
- Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
More Guidelines- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer